Addressing Skin Pain in Atopic Dermatitis By Tori Rodriguez, MA, LPC, AHC The burden of pain as a component of atopic dermatitis treatment should be assessed and managed in a thorough manner.
Factors Associated With More Severe AD in Children By Brandon May Factors associated with severe atopic dermatitis in later childhood and self-reported triggers are reported.
Patients With Hand Eczema Report High Levels of Stress By Brandon May The clinic-etiological factors of patients with hand eczema were assessed.
Upadacitinib Bests Dupilumab in Atopic Dermatitis Trial By Brian Park, PharmD The randomized, double-blind, double-dummy, active-controlled Heads Up study included 692 patients aged 18 to 75 years with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Atopic Dermatitis Linked to Increased Risk for Autoimmune Disease By Brandon May The association of atopic dermatitis and autoimmune disease was investigated.
Weak Evidence of Causal Relationship of Vitamin D and Atopic Dermatitis By Colby Stong The causal effect of genetically predicted vitamin D levels on atopic dermatitis risk was investigated.
Increased Conjunctivitis Risk Observed in Patients Initiated Dupilumab for Atopic Dermatitis By Emily Pond The 6-month risk for conjunctivitis in patients with atopic dermatitis treated with dupilumab was evaluated.
Atopic Dermatitis Does Not Appear to Affect COVID-19 Severity By Chen Fang, PharmD, RPh Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Abrocitinib Associated With Less Flare in Atopic Dermatitis Trial By Diana Ernst, RPh The JADE REGIMEN trial was a responder-enriched, placebo-controlled withdrawal study that included a 12-week open-label run-in period.
EASI 50, SCORAD 35, and O-SCORAD 35 May Be Most Meaningful MICs for Atopic Dermatitis By Colby Stong The minimal important changes of percentage and absolute improvement of EASI and SCORAD scores in adults and children with AD was determined.
Topical Live Biotherapeutic Gets Fast Track Status for Atopic Dermatitis By Brian Park, PharmD FB-401 is a topically applied live biotherapeutic that consists of 3 therapeutic strains of commensal Roseomonas mucosa.